Cover Image
市場調查報告書

亞洲的胚胎著床前遺傳基因診斷 (PGD) 市場 (非整倍體篩檢,染色體異常,男女性別選擇,組織相容抗原檢查,單一遺傳基因疾病,X連鎖疾病):產業分析,市場規模、佔有率、成長率、趨勢、預測

Preimplantation Genetic Diagnosis Market (Aneuploidy Screening, Chromosomal Aberrations, Gender Selection, HLA Typing, Single Gene Disorder, and X-linked diseases) - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 356397
出版日期 內容資訊 英文 114 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
亞洲的胚胎著床前遺傳基因診斷 (PGD) 市場 (非整倍體篩檢,染色體異常,男女性別選擇,組織相容抗原檢查,單一遺傳基因疾病,X連鎖疾病):產業分析,市場規模、佔有率、成長率、趨勢、預測 Preimplantation Genetic Diagnosis Market (Aneuploidy Screening, Chromosomal Aberrations, Gender Selection, HLA Typing, Single Gene Disorder, and X-linked diseases) - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023
出版日期: 2016年03月28日 內容資訊: 英文 114 Pages
簡介

本報告提供亞洲各國的胚胎著床前遺傳基因診斷 (以下PGD) 市場現況與未來展望相關分析,診斷技術概要和相關疾病,市場基本結構,主要的推動及阻礙市場要素,整體市場趨勢預測 (過去3年、今後8年份),各檢查項目、各終端用戶詳細趨勢,各地區、主要國家的市場結構及趨勢預測,法規環境,主要企業簡介等相關調查。

第1章 序論

第2章 摘要整理

第3章 亞洲的胚胎著床前遺傳基因診斷 (PGD) 市場概要

  • 簡介
  • 市場動態
    • 推動因素
    • 阻礙因素
    • 市場機會
  • 波特的五力分析
  • 胚胎著床前遺傳基因診斷 (PGD) 概要
    • PGD的症狀
    • PGD的一次候補藥
    • PGD的併發症
    • 優點和缺點
    • PGD的技術 (FISH,PCR,CGH等)
    • 技術的限制
    • PGD的風險
    • 平均費用分析
  • PGD的法規政策、法律體制:亞洲的主要國家的情況
  • 市場誘因:各國
  • 熱圖分析:主要企業的情況
  • PGD中心的數量:各國

第4章 檢驗的各種類的市場收益額 (以金額為準,總計11年份)

  • 概要
  • 非整倍體篩檢
  • 染色體異常
  • 男女性別選擇
  • 組織相容抗原檢查
  • 單一遺傳基因疾病
  • X連鎖疾病

第5章 各終端用戶的市場收益額 (以金額為準,總計11年份)

  • 概要
  • 不孕治療診所
  • 醫療設施
  • 學術機構、研究中心

第6章 各地區的市場收益額 (以金額為準,總計11年份)

  • 概要
  • 東南亞
    • 印尼
    • 馬來西亞
    • 菲律賓
    • 新加坡
    • 泰國
    • 其他
  • 東亞
    • 中國
    • 日本
    • 韓國
    • 其他
  • 南亞
    • 印度
    • 斯里蘭卡
    • 其他
  • 中亞
  • 西亞
    • 以色列
    • 土耳其
    • 約旦
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國 (UAE)
    • 其他

第7章 目前市場趨勢與建議

第8章 企業簡介

  • Genesis Genetics
    • 企業概要
    • 財務概要
    • 產品系列
    • 產業策略
    • 近幾年趨勢
  • Genea Ltd.
  • Illumina, Inc.
  • Laboratory Corporation of America Holdings (LabCorp)
  • Natera, Inc
  • PerkinElmer, Inc.
  • Quest Diagnostics, Inc.
  • Repro Genetics
  • Reproductive Genetics Innovations
  • 其他
目錄

Title: Preimplantation Genetic Diagnosis Market (Aneuploidy Screening, Chromosomal Aberrations, Gender Selection, HLA Typing, Single Gene Disorder, and X-linked diseases; Fertility Clinics, Health Care Facilities, and Academic Institutes and Research Centers) - Asia Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.

Preimplantation genetic diagnosis (PGD) is the inspection of an embryo in vitro in order to eliminate a genetic condition in case a high risk of that condition is known. PGD is an evolving technique that provides a practical alternative to prenatal diagnosis and termination of pregnancy for couples who are at substantial risk of transmitting a serious genetic disorder to their offspring. Growing incidence of infertility across the world is the major driver of the PGD market. Preimplantation genetic diagnosis plays an important role in the detection and determination of genetic disorders, sex-linked diseases, and chromosomal abnormalities in the embryo before IVF can be performed. Rising incidence of infertility coupled with growing awareness about IVF and PGD is the major factor driving the PGD market in Asia.

The preimplantation genetic diagnosis (PGD) market in Asia has been segmented based on test type, end-user, and geography. Based on test type, the market has been segmented into aneuploidy screening, chromosomal aberrations, gender selection, HLA typing, single gene disorder, and X-linked diseases. The market analysis is based on market size and forecast in terms of US$ Mn for the period 2013 to 2023 along with the compound annual growth rate (CAGR %) for the period 2015 to 2023, considering 2014 as the base year. The aneuploidy screening segment accounted for the largest share of 35% of the PGD market in Asia in 2014. Based on end-user, the market has been segmented into fertility clinics, health care facilities (including hospitals, diagnostic centers, and health care facilities), and academic institutes and research centers.

The market overview section of the report demonstrates major market dynamics such as drivers, restraints, and opportunities that influence the current and future status of the industry. The market overview section includes Porter's Five Forces Analysis, overview of PGD, Regulatory Policies and Legality Framework for PGD, Heat Map Analysis for key market players, and country-wise number of PGD Centers in Asia. The report provides a detailed industry analysis of the preimplantation genetic diagnosis (PGD) market in Asia with the help of market attractiveness analysis, by geography, for the year 2014.

The market has been analyzed for Asia covering South Eastern Asia, Eastern Asia, Southern Asia, Central Asia, and Western Asia. The market size and forecast of the regional and country-wise markets is provided for the period 2013 to 2023. CAGR (%) for each region is also estimated for the period 2015 to 2023, considering 2014 as the base year. South Eastern Asia includes Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Rest of SEA. Eastern Asia comprises China, Japan, South Korea, and Rest of Eastern Asia. Southern Asia constitutes India, Sri Lanka, and Rest of Southern Asia. Western Asia includes Israel, Turkey, Jordan, Saudi Arabia, the United Arab Emirates, and Rest of Western Asia. Eastern Asia accounted for the largest share of the PGD market in Asia.

The report also provides recommendations for market players and new entrants. These recommendations would enable existing market players to expand their market shares and help new companies to establish their presence in the PGD market in Asia. The report concludes with the company profiles section, which includes key information about major players in the market such as financial overview, business strategies, and recent developments. Major players in this market are Genesis Genetics (U.S.), Genea Limited (Australia), Illumina, Inc. (U.S.), Laboratory Corporation of America Holdings (U.S.), Natera, Inc. (U.S.), PerkinElmer, Inc.(U.S.), Quest Diagnostics Incorporated (U.S.), Reprogenetics (U.S.), and Reproductive Genetics Innovations LLC (U.S.). The market share analysis of key players involved the study of company products or services portfolio, post sales services and maintenance, sales revenue, and its geographical presence.

The PGD market in Asia has been segmented as follows:

Asia Preimplantation Genetic Diagnosis (PGD) Market, by Test Type

  • PGD for Aneuploidy Screening
  • PGD for Chromosomal Aberrations
  • PGD for Gender Selection
  • PGD for HLA Typing
  • PGD for Single Gene Disorder
  • PGD for X-linked diseases

Asia Preimplantation Genetic Diagnosis (PGD) Market, by End-user

  • Fertility Clinics
  • Health Care Facilities (including hospitals, diagnostic centers, and health care facilities)
  • Academic Institutes and Research Centers

Asia Preimplantation Genetic Diagnosis (PGD) Market, by Geography

  • South Eastern Asia
    • Indonesia
    • Malaysia
    • Philippines
    • Singapore
    • Thailand
    • Rest of SEA
  • Eastern Asia
    • China
    • Japan
    • South Korea
    • Rest of Eastern Asia
  • Southern Asia
    • India
    • Sri Lanka
    • Rest of Southern Asia
  • Central Asia
  • Western Asia
    • Israel
    • Turkey
    • Jordan
    • Saudi Arabia
    • United Arab Emirates
    • Rest of Western Asia

Table of Contents

Chapter 1 - Introduction

  • 1.1. Report Description
  • 1.2. Research Methodology
  • 1.3. Market Segmentation

Chapter 2 - Executive Summary

Chapter 3 - Asia Preimplantation Genetic Diagnosis (PGD): Market Overview

  • 3.1. Introduction
  • 3.2. Market Dynamics
    • 3.2.1. Drivers
    • 3.2.2. Restraints
    • 3.2.3. Opportunities
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Bargaining Power of Buyers
    • 3.3.3. Threat of New Entrants
    • 3.3.4. Threat of Substitutes
    • 3.3.5. Competitive Rivalry
  • 3.4. Overview of PGD
    • 3.4.1. Indications and Conditions for PGD
    • 3.4.2. Primary Candidates for PGD
    • 3.4.3. Complications Associated with PGD
    • 3.4.4. Advantages and Disadvantages
    • 3.4.5. Techniques used for PGD (e.g. FISH, PCR, CGH, etc.)
    • 3.4.6. Limitations of Techniques
    • 3.4.7. Risk of PGD
    • 3.4.8. Average Cost Analysis
  • 3.5. Regulatory Policies and Legality Framework for PGD: Major Countries of Asia
  • 3.6. Market Attractiveness Analysis: Asia Preimplantation Genetic Diagnosis (PGD) Market, by Geography, 2014
  • 3.7. Heat map analysis for key market players
  • 3.8. Number of PGD centers, By Country

Chapter 4 - Asia Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million), by Test Type, 2013 - 2023

  • 4.1. Overview
  • 4.2. Aneuploidy Screening
  • 4.3. Chromosomal Aberrations
  • 4.4. Gender Selection
  • 4.5. HLA Typing
  • 4.6. Single Gene Disorder
  • 4.7. X-linked diseases

Chapter 5 - Asia Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million), by End-user, 2013 - 2023

  • 5.1. Overview
  • 5.2. Fertility Clinics
  • 5.3. Healthcare Facilities
  • 5.4. Academic Institutes and Research Centers

Chapter 6 - Asia Preimplantation Genetic Diagnosis (PGD) Market Revenue (USD Million), by Geography, 2013 - 2023

  • 6.1. Overview
  • 6.2. South Eastern Asia
    • 6.2.1. Indonesia
    • 6.2.2. Malaysia
    • 6.2.3. Philippines
    • 6.2.4. Singapore
    • 6.2.5. Thailand
    • 6.2.6. Rest of SEA
  • 6.3. Eastern Asia
    • 6.3.1. China
    • 6.3.2. Japan
    • 6.3.3. South Korea
    • 6.3.4. Rest of Eastern Asia
  • 6.4. Southern Asia
    • 6.4.1. India
    • 6.4.2. Sri Lanka
    • 6.4.3. Rest of Southern Asia
  • 6.5. Central Asia
  • 6.6. Western Asia
    • 6.6.1. Israel
    • 6.6.2. Turkey
    • 6.6.3. Jordan
    • 6.6.4. Saudi Arabia
  • 6.6.5. United Arab Emirates
    • 6.6.6. Rest of Western Asia

Chapter 7 - Current Trends and Recommendations

Chapter 8 - Company Profiles

  • 8.1. Genesis Genetics
    • 8.1.1. Company Overview
    • 8.1.2. Financial Overview
    • 8.1.3. Product Portfolio
    • 8.1.4. Business Strategies
    • 8.1.5. Recent Developments
  • 8.2. Genea Ltd.
  • 8.3. Illumina, Inc.
  • 8.4. Laboratory Corporation of America Holdings (LabCorp)
  • 8.5. Natera, Inc
  • 8.6. PerkinElmer, Inc.
  • 8.7. Quest Diagnostics, Inc.
  • 8.8. Repro Genetics
  • 8.9. Reproductive Genetics Innovations
  • 8.10. Others
Back to Top